The novel aldosterone inhibitor works, but longer-term safety data are needed before the drug might be approved.

The choice between ICD types still should be based on each individual patient’s risk factors, Kenneth Ellenbogen says.

The US guidelines are likely to change following the release of the VANISH2 results last year, Christine Albert anticipates.

The benefit of GLP-1 therapy couldn’t be explained by weight loss, suggesting that some pleiotropic effects may be at work.

Complications weren’t more common when leads were extracted. Yet there’s also the option of “jailing” leads instead.

It’s no surprise that complications can vex concomitant procedures. But when staged, should PCI or TAVI come first?

With careful consideration of several factors, many patients can avoid an overnight stay, reducing costs without sacrificing ...

In aneurysms normally chosen for surveillance, the endovascular technique slowed growth by 70% in the small phase I trial.

The novel dissolvable therapy had a 93.2% probability of being cost-effective at a modest willingness-to-pay level.

Especially given its impact on cardiology, the WHI should be the “pride” of the US, not on the chopping block, says Martha ...

Ten years after learning their polygenic risk score, patients had fewer events—perhaps due to greater use of statin therapy.

SGLT2 inhibitors and GLP-1 agonists are class 1 medications, but many Medicaid patients have challenges with access.